Sort   by:  
 Page size 
TranscriptomicsATAC-seq in control compared to ZEB1 knock-down MDA-MB-231 cells
Identification of open chromatin regions in wildtpye, control knock-down (shCtrl) and ZEB1 knock-down (shZEB1) human breast cancer MDA-MB-231 cells by ATAC(Assay for transposable-accessible chromatin)-seq.
ORGANISM(S): Homo sapiens 
2020-07-22 | E-MTAB-8264 | biostudies-arrayexpress
GenomicsChIP-seq for ZEB1 in the human breast cancer cell line MDA-MB-231
Identification of DNA binding sites of the transcription factor ZEB1 in the human breast cancer cell line MDA-MB-231 by chromatin-immunoprecipitation followed by sequencing (ChIP-seq).
ORGANISM(S): Homo sapiens 
2020-07-22 | E-MTAB-8258 | biostudies-arrayexpress
TranscriptomicsMicroRNA profiling of human mammary or colon cancer cell lines with stable knock down of ZEB1
Expression of a panel of miRNAs was analyzed in three different cell lines comparing stable knock down of ZEB1 (shZEB) to control transfected cell lines. The analyzed cell lines derived of mammary (MDA MB 231) or colon cancer (SW480, HCT116).
ORGANISM(S): Homo sapiens 
2008-06-01 | E-TABM-461 | biostudies-arrayexpress
TranscriptomicsGene expression analysis of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type
Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the chan...
ORGANISM(S): Homo sapiens 
2015-09-15 | E-MTAB-3387 | biostudies-arrayexpress
TranscriptomicsmicroRNA profiling of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type
Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the chan...
ORGANISM(S): Homo sapiens 
2015-09-15 | E-MTAB-3391 | biostudies-arrayexpress
TranscriptomicsGene expression analysis of Panc1 pancreatic cancer cells with shRNA mediated control (GFP) or ZEB1 knockdown
Epithelial-to-mesenchymal transition (EMT) is a fundamental process in development and disease. If aberrantly activated it is a trigger for tumour progression and metastasis (Thiery et al 2009 Cell). It is now known that EMT activation is also associated with the maintenance of stem-cell properties ...
ORGANISM(S): Homo sapiens 
2016-06-15 | E-MTAB-3483 | biostudies-arrayexpress
TranscriptomicsGene expression analysis of MDA MB 231 basal type breast cancer cells with shRNA mediated control (GFP) or ZEB1 knockdown
Epithelial-to-mesenchymal transition (EMT) is a fundamental process in development and disease. If aberrantly activated it is a trigger for tumour progression and metastasis (Thiery et al 2009 Cell). It is now known that EMT activation is also associated with the maintenance of stem-cell properties ...
ORGANISM(S): Homo sapiens 
2015-09-15 | E-MTAB-3482 | biostudies-arrayexpress
TranscriptomicsGene expression analysis of HCT116 colorectal cancer cells with shRNA mediated control (GFP) or ZEB1 knockdown
Epithelial-to-mesenchymal transition (EMT) is a fundamental process in development and disease. If aberrantly activated it is a trigger for tumour progression and metastasis (Thiery et al 2009 Cell). It is now known that EMT activation is also associated with the maintenance of stem-cell properties ...
ORGANISM(S): Homo sapiens 
2016-06-15 | E-MTAB-3480 | biostudies-arrayexpress
Sort   by:  
 Page size